The Client
- US-based biotech with a portfolio of CNS gene therapies in early-stage development for neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies
Challenge
- The biotech was looking to capitalize on a sudden surge of pharma interest in neurology to facilitate favorable deal terms on a pre-IND gene therapy program
- The company needed to quickly gather the necessary materials and information in order to pitch and value their program and respond to in-bound interest
Approach
- Held discussions with internal commercial and R&D stakeholders to determine value proposition & align on partnering strategy
- Performed a deal benchmarking analysis to uncover the defensible deal value in the relevant indication
- Identified qualified partners and socialized the product concept to solicit feedback and gauge partnering interest
Valued Outcome
- Instilled readiness to engage with potential partners, including guidance on deal value/structure, development of pitch deck and term sheet, and insights for successful partnering and deal negotiation
- ID’d and obtained feedback from target partners
- Helped elucidate the value proposition and anticipate and address likely due diligence questions